CXW

Analyst Note: CoreCivic, Inc. (CXW)

Date: 2026-06-13 Current Price: $28.90

1. Structural Readiness

• Conservative Entry: Unknown.
• Breakout Level: Unknown.
• Extension: Unknown.
• ATR Context: Current ATR is 3.5% (productive). This falls within the historical "sweet spot" (4–6% is the canonical high, but 3.5% indicates active, manageable volatility suitable for position sizing, though not the absolute highest historical volatility bucket).

2. Thesis Layer

As of 2026-06-13, there is no named secular thesis attached to this specific tactical setup. The investment case is not driven by a broad macro narrative (e.g., "The Great Reopening" or "AI Infrastructure") but is strictly setup-led. The conviction must be derived entirely from the quality of the business fundamentals, the strength of the management guidance, and the structural readiness of the price action (once the missing pivot data is available). We judge this name on its operational execution and financial metrics, not on invented macro themes.

3. Business Overview

CoreCivic, Inc. operates as a provider of correctional and detention services, residential reentry centers, and government real estate solutions. The company is organized into three distinct divisions: CoreCivic Safety, CoreCivic Community, and CoreCivic Properties.

• Revenue Model & Customer Concentration: The business is heavily reliant on federal government contracts. As of Q1 2026, Federal partners (primarily ICE and the U.S. Marshals Service) comprised 58% of total revenue. Specifically, ICE accounted for 35% and the USMS for 18% of total revenue in 2025.
• Operational Scale: As of March 31, 2026, the company operated 44 correctional and detention facilities (40 owned/leased) with a design capacity of 68,000 beds. Additionally, the CoreCivic Community segment operated 20 residential reentry centers with a capacity of 4,000 beds.
• Recent Strategic Acquisitions:
• Clinical Solutions Pharmacy (CSP): Acquired on April 1, 2026. CSP is a leading provider of mail-order pharmacy services to correctional facilities, filling ~60,000 prescriptions daily with 50% automation. It serves over 600 facilities, with no single customer exceeding 15% of its revenue.
• Farmville Detention Center: Acquired July 1, 2025. This 736-bed facility serves adult male non-citizens under an IGSA with ICE, expiring in March 2029.
• Demand Drivers: Management reports a significant increase in demand. Populations from ICE in care increased by 4,500 individuals (45%) from the start of 2025 through March 31, 2026. Federal revenues grew 19.1% year-over-year in 2025 ($1.0B to $1.19B).
• Idle Capacity: As of December 31, 2025, the company had five idle facilities (approx. 7,000 beds) with core staffing in place, actively being marketed to potential customers.

4. Archetype and Conviction

• Archetype: Quality Compounder (with strong Cyclical Recovery characteristics).
• *Rationale:* The company demonstrates a "Quality Compounder" profile through its ability to generate consistent earnings growth, manage cash flow (AFFO), and execute accretive acquisitions (CSP, Farmville). The "Cyclical Recovery" element is evident in the activation of idle facilities and the 19.1% revenue growth driven by policy shifts (OBBBA) and increased ICE populations.
• Valuation & Financials:
• Guidance (May 2026): Management expects diluted EPS of $1.51 to $1.61 and Adjusted EPS of $1.53 to $1.63 for 2026.
• Cash Flow: Adjusted Funds From Operations (AFFO) is projected at $250.4M to $264.9M for 2026.
• Consensus: Forward consensus EPS for FY1 is $1.57, and FY2 is $1.825.
• Conviction Stack:
• Thesis Strength: Moderate (Tactical, no macro thesis).
• Evidence Quality: High. Multiple primary sources (earnings transcripts, SEC filings) confirm strong operational metrics and clear management guidance.
• Structural Quality: Unknown (Missing price action data).
• Rerating Potential: Moderate. The acquisition of CSP and the activation of idle beds provide a clear path to margin expansion and revenue growth, which could support a multiple expansion if the market re-rates the company from a "cyclical operator" to a "growth compounder."

5. Invalidations, Strengths, and Gaps

• What Would Strengthen the Case:
• Further announcements of idle facility activations beyond the five currently marketed.
• Continued growth in AFFO exceeding the upper end of the $264.9M guidance.
• What Would Invalidate the Case:
• A significant reduction in ICE populations or a policy shift reducing federal detention contracts.
• Failure to integrate CSP or Farmville as expected, leading to missed EPS guidance.
• Gaps in Evidence:
• Missing ATR at Breakout: We have the current ATR (3.5%) but not the ATR at the moment of a potential breakout, which is required to assess structural quality.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management guidance for 2026 EPS of $1.51-$1.61 and AFFO of $250.4M-$264.9M; 19.1% YoY growth in federal revenues; acquisition of CSP and Farmville Detention Center expanding capacity and services. Structural Readiness Expected path: Management expects to activate idle facilities and realize returns from recent acquisitions, driving EPS growth toward the upper end of guidance. Expected horizon: 12 to 18 months for the full realization of acquisition synergies and facility activations.